Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, insulin detemir, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 60
States / cities: Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more

Conditions: Advanced Solid Malignancies
Interventions: CT7001, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Chronic Urticaria
Interventions: Stress intervention; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Facioscapulohumeral Muscular Dystrophy
Interventions: FSHD-specific functional rating scale, Electrical Impedance Myography; Diagnostic Test · Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 5 more

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: Time restricted feeding (TRF), Daily calorie restriction; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Abiraterone acetate; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Solid Tumours
Interventions: CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Hepatic Impairment
Interventions: WCK 2349; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity
Interventions: endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy Subjects (HS)
Interventions: zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Sickle Cell Disease
Interventions: GBT440; Drug
Lead sponsor: Global Blood Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Non-Central Nervous System (CNS) Malignancies
Interventions: Oprozomib, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Obesity
Interventions: Weight Management Program (WMP), Medication for chronic weight management (Rx); Other · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: CS0159; Drug
Lead sponsor: Cascade Pharmaceuticals, Inc; Other
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Respiratory Aspiration of Gastric Contents
Interventions: Interview questionnaire, Gastric ultrasound exam; Behavioral · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: COVID - 19
Interventions: PA-001; Drug
Lead sponsor: PeptiDream Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Diabetes Care Center; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Salinas, California

Conditions: Healthy Volunteers
Interventions: 300 mg/day of dietary supplement containing carrageenan; Dietary Supplement
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 25 Years to 69 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Healthy
Interventions: Gabapentin 800 mg tablets, single dose (1 tablet), NEURONTIN® 400 mg capsules, single dose (2 capsules); Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hunger
Interventions: High Dose Supplement, Low Dose Supplement, Placebo; Dietary Supplement
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Neuromuscular Disease, Motor Neuron Disease, Inherited Neuromuscular Conditions, Inherited Neuropathies
Interventions: EIM testing, Nerve & muscle ultrasonography, Nerve conduction studies, Electromyography (EMG); Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 2 Years to 110 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-831; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered Fed low calorie, Palbociclib administered Fed moderate calorie; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Stress Intervention for Chronic Urticaria

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Time Restricted Eating for the Treatment of Type 2 Diabetes

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Routine Validation and Reproducibility Testing of Laboratory Measures and Research Techniques Used for Metabolism Research (VAL)

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

Gastric Ultrasound for Estimation of the Aspiration Risk Study

PA-001 Ph.1 Study in Healthy and Elderly Subjects

CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target

Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers

A Limited Food Effect Study of Gabapentin 800 mg Tablets

Effect of Supplement on Appetite and GLP-1

Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption